After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

This press release is a paid promotional commentary issued by Equity Insider on behalf of GT Biopharma (GTBP), focusing on the natural killer (NK) cell immunotherapy sector. Compass Therapeutics (CMPX) is mentioned solely as a peer in the broader immune-engager and bispecific landscape, illustrating investor interest in scalable alternatives to cell therapy.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.